-
1.发明公开PARTICLES OF N-(5-CYANO-4-((2-METHOXYETHYL)AMINO)PYRIDIN-2-YL)-7-FORMYL-6-((4-METHYL-2- OXOPIPERAZIN-1-YL)METHYL)-3,4-DIHYDRO-1,8-NAPHTHYRIDINE-1(2H)-CARBOXAMIDE 审中-公开N-（5-氰基-4 - （（2-甲氧基乙基）氨基）吡啶-2-基）-7-甲基-6 - （（4-甲基-2-氧代哌嗪-1-基）甲基）-3 -1,4-二氢-1,8-二氮杂萘-1（2H） - 甲酰胺
公开(公告)号：EP3274349A1
公开(公告)日：2018-01-31
申请号：EP16712082.3
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert , MALLET, Franck , MARTZ, Julie , LIAO, Lv , XIONG, Jing , HAN, Bo , WANG, Can , ZHAO, Xianglin
IPC分类号： C07D471/04 , A61K31/4375 , A61P35/00
摘要： The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
-
公开(公告)号：EP3274344A1
公开(公告)日：2018-01-31
申请号：EP16712081.5
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert
IPC分类号： C07D401/14 , C07D213/75 , C07D401/12 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号： C07D401/12 , A61K31/4427 , C07D213/75 , C07D401/14 , C07D405/14
摘要： a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
-
公开(公告)号：EP3274349B1
公开(公告)日：2020-04-22
申请号：EP16712082.3
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert , MALLET, Franck , MARTZ, Julie , LIAO, Lv , XIONG, Jing , HAN, Bo , WANG, Can , ZHAO, Xianglin
IPC分类号： C07D471/04 , A61K31/4375 , A61P35/00
-
公开(公告)号：EP4059934A1
公开(公告)日：2022-09-21
申请号：EP21208454.5
申请日：2017-09-06
申请人： Novartis AG
发明人： ALPER, Phillip , DEANE, Jonathan , JIANG, Songchun , JIANG, Tao , KNOEPFEL, Thomas , MICHELLYS, Pierre-Yves , MUTNICK, Daniel , PEI, Wei , SYKA, Peter , ZHANG, Guobao , ZHANG, Yi
IPC分类号： C07D471/04 , A61K31/437 , A61P37/00
摘要： The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
-
公开(公告)号：EP3510033A1
公开(公告)日：2019-07-17
申请号：EP17777966.7
申请日：2017-09-06
申请人： Novartis AG
发明人： ALPER, Phillip , DEANE, Jonathan , JIANG, Songchun , JIANG, Tao , KNOEPFEL, Thomas , MICHELLYS, Pierre-Yves , MUTNICK, Daniel , PEI, Wei , SYKA, Peter , ZHANG, Guobao , ZHANG, Yi
IPC分类号： C07D471/04 , A61K31/437 , A61P37/00
-
公开(公告)号：EP3274344B1
公开(公告)日：2019-04-24
申请号：EP16712081.5
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert
IPC分类号： C07D401/14 , C07D213/75 , C07D401/12 , A61K31/444 , A61K31/506 , A61P35/00 , C07D405/14 , A61K31/4427
-
公开(公告)号：EP3273959A1
公开(公告)日：2018-01-31
申请号：EP16712083.1
申请日：2016-03-23
申请人： NOVARTIS AG
发明人： BUSCHMANN, Nicole , FAIRHURST, Robin Alec , FURET, Pascal , KNOEPFEL, Thomas , LEBLANC, Catherine , MAH, Robert , LIAO, Lv , XIONG, Jing , HAN, Bo , WANG, Can , GRAUS PORTA, Diana , ZHAO, Xianglin , WARTMANN, Markus , FORTANET, Jorge Garcia , HAFEEZ, Nafeeza , LAMARCHE, Matthew J. , PORTER, Dale
IPC分类号： A61K31/506 , A61K31/4439 , A61K31/513 , A61K31/519 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/496 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K2300/00
摘要： A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
